ACIU — AC Immune SA
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1651625 ·
Last close
$2.11
Market Cap
$209.79M
52W High
$3.90
52W Low
$2.02
ADV30
193,328
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 3,244,000 | — | -9,801,000 | -8,750,000 | 139,208,000 | 18,726,000 | 112,264,000 |
| Jun 2026 | 15,113,000 | — | 1,193,000 | 1,874,000 | 150,401,000 | 27,757,000 | 115,232,000 |
| Mar 2026 | 1,119,000 | — | -14,788,000 | -14,801,000 | 137,421,000 | 19,169,000 | 105,887,000 |
| Dec 2025 | 338,000 | — | -14,406,000 | -14,373,000 | 154,251,000 | 26,795,000 | 109,367,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,262,000
Investing CF
$63,542,000
Financing CF
$-1,020,000
CapEx
$-900,000
Dividends Paid
—
Buybacks
$-5,000
EPS Diluted TTM
$-0.65
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-459,254,000
Inventory
—
Receivables
$4,063,000
ST Investments
$55,186,000
EBIT TTM
$-35,823,000
Pretax Income TTM
$-36,050,000
Interest Exp TTM
$227,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,509,000
EBITDA
$-42,479,000
Free Cash Flow
$-33,138,624
Enterprise Value
$203,163,328
Total Cash
$75,357,000
Total Debt
$4,102,000
Shares Out
99,426,932
Trailing EPS
$-0.53
Book Value
$0.44
ROE
-78.5%
ROA
-16.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 3,573,000 | -68,863,000 | -70,447,000 | 154,251,000 | 109,367,000 | 44,884,000 | -69,262,000 |
| Dec 2024 | 27,309,000 | -52,378,000 | -50,916,000 | 230,913,000 | 118,643,000 | 112,270,000 | 65,842,000 |
| Dec 2023 | 14,801,000 | -53,624,000 | -54,233,000 | 182,814,000 | 22,171,000 | 160,643,000 | -60,408,000 |
| Dec 2022 | 3,935,000 | -70,847,000 | -70,753,000 | 185,938,000 | 16,947,000 | 168,991,000 | -73,568,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.60
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $2.10 · call volume: 90 · put volume: 1
Expected Move to 2026-12-18:
±$0.68
(32.38%) —
implied range
$1.42 –
$2.78
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NGEN | NERVGEN PHARMA CORP. | $210.74M | $1.96 | — |
| LAB | STANDARD BIOTOOLS INC. | $212.95M | $0.54 | — |
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | $205.29M | $1.90 | — |
| PRLD | Prelude Therapeutics Inc | $216.05M | $3.32 | — |
| DRUG | BRIGHT MINDS BIOSCIENCES INC. | $201.25M | $20.51 | — |
News headlines (Yahoo Finance, 1h cache)
AC Immune to Present at Jefferies Global Healthcare Conference 2026
2026-11-11 12:00 · Yahoo
AC Immune (ACIU) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 12:55 · Yahoo
AC Immune: Q3 Earnings Snapshot
2026-11-04 12:25 · Yahoo
AC Immune Third Quarter 2026 Financial and Corporate Update
2026-11-04 12:00 · Yahoo
Ionis' Tryngolza Gets EU Approval for Severe Hypertriglyceridemia
2026-11-18 16:34 · Yahoo
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
2026-11-18 15:35 · Yahoo
Xenon Stock Rises 12% in the Past Month on Pipeline Progress
2026-11-17 15:11 · Yahoo
Summit Stock Falls on FDA Rejection for Lung Cancer Drug
2026-11-16 16:13 · Yahoo
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
2026-11-13 15:41 · Yahoo
CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates
2026-11-13 13:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.